A23: Oncologic Disease- Tumor Markers



Similar documents
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Ovarian tumors Ancillary methods

Laboratory examination in patients with tumours

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Tumor Markers. What are tumor markers? How are tumor markers used? Screening and early detection of cancer

Index. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, HT, see Serotonin

Neuroendocrine Tumors

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download

Immunohistochemical differentiation of metastatic tumours

- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

MEDICAL POLICY SUBJECT: SERUM TUMOR MARKERS FOR DIAGNOSIS AND MANAGEMENT OF CANCER. POLICY NUMBER: CATEGORY: Laboratory Test

TUMOUR MARKERS : AN OVERVIEW

Gastrointestinal and pancreatic neuroendocrine tumours. Dr. med. Henrik Csaba Horváth

Novel Radionuclide Therapies in Oncology : Promising Area in the Field of Nuclear Medicine

NEU IM PROGRAMM. LOXO Antikörper für die Immunhistochemie (alphabetisch nach Bezeichnung sortiert) Art.Code Artikelbezeichnung Typ Einsatz Einheit

Lessons from a consultation practice

Thursday, November 3, 2005

4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma

Frequently Asked Questions About Ovarian Cancer

How To Test For Cancer With A Blood Test

Non-Functioning Pancreatic Neuroendocrine Tumours

Effusions: Mesothelioma and Metastatic Cancers

Update on Mesothelioma

High-Grade Neuroendocrine Tumours. NET Patient Foundation

A 70-year old Man with Pleural Effusion

National Medical Policy

THYROID CANCER. I. Introduction

Practical Effusion Cytology

How To Raise Money For Rare Cancer Research

Aktualne reguły leczenia nowotworów neuroendokrynnych przewodu pokarmowego

Screening Guidelines for Malignancy Michael T. Milano, MD PhD

Günter Klöppel Dept. of Pathology Consultation Center for Pancreatic and Endocrine tumors Technische Universität München

Pathology of lung cancer

CatalogNo Product Name Size

National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)

Definitions. Carcinoma. Sarcoma Any cancer of connective tissue, e.g. muscle, fat, bone, lymphatic vessels.

Cancer: DNA Synthesis, Mitosis, and Meiosis

Lung Cancer: More than meets the eye

New Hampshire Childhood Cancer

Number. Source: Vital Records, M CDPH

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS

BRCA1 and BRCA2 for men

Screening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group

page antibody Adipophilin (polyclonal) ALDH1A1 (44) c-myc (EP121) * Cadherin-17 (SP183) Cathepsin K (3F9)

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

Neuroendocrine Tumors: Classification and Pathological Categorization

The Diagnosis of Cancer in the Pathology Laboratory

Fulfilling the Promise

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Diagnosis of Mesothelioma Pitfalls and Practical Information

Immunohistochemistry of soft tissue tumors

Future Oncology: Technology, Products, Market and Service Opportunities

Survivorship Care Plans Guides for Living After Cancer Treatment

Report series: General cancer information

NOVEL PLATFORMS FOR CANCER DIAGNOSIS

Co-pay assistance organizations offering assistance

Seattle. Case Presentations. Case year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Cigna Medical Coverage Policy

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

NEOPLASIA (4) Tumor-Host Interactions and Systemic Effects of Neoplasms

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Pediatric Oncology for Otolaryngologists

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.

The Need for Accurate Lung Cancer Staging

Adjuvant Therapy for Breast Cancer: Questions and Answers

How do we diagnose cancer today?

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Cancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi File No. 23(01)2014/Div.

Developments in Biomarker Identification and Validation for Lung Cancer

Guide to Understanding Breast Cancer

International System of Units (SI Units)

Your Guide to the Breast Cancer Pathology Report

dedicated to curing BREAST CANCER

Small Cell Lung Cancer

3 Summary of clinical applications and limitations of measurements

Male. Female. Death rates from lung cancer in USA

Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.

Cancer Drug Coverage: Putting IV and Orally Administered Drugs on an Equal Footing. Deb Maskens Kidney Cancer Canada

The Carcinoma of Unknown Primary (CUP) service at Guys and St Thomas Hospital

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner

Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.

Normal values of IGF1 and IGFBP3. Kučera R., Vrzalová J., Fuchsová R., Topolčan O., Tichopád A.

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all.

Lung Cancer Research: From Prevention to Cure!

Biochemistry of Cancer Cell

PROTOCOL OF THE RITA DATA QUALITY STUDY

Breakthrough Treatment Options for Breast Cancer

Group Critical Illness Insurance

Neoplasms of the LUNG and PLEURA

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

Transcription:

A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of tumor markers and genetic markers. Gastrointestinal Tumor Type Marker Recommended Use Recommending Organizations* Hepatic AFP Monitoring ACS,, ESMO, NACB Early detection in ACS,, ESMO, NACB high-risk patients Helicobacter Environmental risk pylori factor E-Cadherin Risk factor in mutations hereditary forms Pancreatic CA19-9 Monitoring, ESMO, NACB (ductal Diagnosis, NACB adenocarcinoma) Colorectal CEA Monitoring ASCO, NACB, ESMO, Monitoring advanced ASCO, NACB disease Prognosis ASCO, ACS, ESMO,, NACB (if used with other prognostic features) ACS = American Cancer Society, = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, ASCO = American Society of Clinical Oncology, NACB = National Academy of Clinical Biochemistry *Organization also searched: American Gastroenterological Association Neuroendocrine Tumor Type Marker Recommended Use All neuroendocrine Chromogranin A Diagnosis tumors (IHC) Recurrence Monitoring Recommending Organizations, ESMO, NACB NACB NACB

Synaptophysin Diagnosis (IHC) Prolactin Diagnosis Ki-67 (MIB-1) Diagnosis (IHC) Carcinoid 5-HIAA (urine) Diagnosis, ESMO, NACB Monitoring for, ESMO, NACB specific tumor Serotonin Diagnosis NACB Chromogranin A Diagnosis and (serum, IHC) Gastrin Diagnosis and Pancreatic Diagnosis and polypeptide Gastrinoma Gastrin Diagnosis and, ESMO, NACB Glucagonoma Glucagon Diagnosis and, ESMO, NACB Pheochromocytoma Metanephrines Diagnosis and, ESMO, NACB (plasma, urine) Catecholamines Diagnosis and, ESMO, NACB (urine) Insulinoma Proinsulin Diagnosis and, ESMO, NACB Insulin Diagnosis and C-peptide Diagnosis and Pituitary Growth hormone Diagnosis and, ESMO, NACB IGF-1 Diagnosis and Prolactin Diagnosis and LH/FSH Diagnosis and TSH Diagnosis and Alpha subunit Diagnosis and ACTH Diagnosis and VIPoma VIP Diagnosis and, ESMO, NACB Pancreatic Pancreatic Diagnosis and, ESMO, NACB neuroendocrine polypeptide

carcinoma Calcitonin Diagnosis and PTH-related peptide Diagnosis and Somatostatin Diagnosis and = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry Lung Tumor Type Marker Recommended Use Recommending Organizations* Small cell NSE (serum, IHC) Monitoring ACS, NACB (SCLC) Prognosis NACB Chromogranin A Prognosis NACB Non-small cell CEA, SCC Ag Monitoring, NACB, ASCO (NSCLC) prognosis, detecting relapse Mesothelioma Soluble mesothelin Monitoring IMIG, NACB, related peptides (Mesomark ) CK 5,6 Diagnosis CEA Diagnosis WT-1 Diagnosis TTF-1 Diagnosis ACS = American Cancer Society, ASCO = American Society of Clinical Oncology, IMIG = International Mesothelioma Interest Group, NACB = National Academy of Clinical Biochemistry, = National Comprehensive Cancer Network *Organizations also searched: American Thoracic Society (ATS), British Thoracic Society (BTS), American College of Chest Surgeons (ACCP)

Female Gynecologic/Genitourinary Tumor Type Marker Recommended Use Recommending Organizations Breast Estrogen, Predict hormone ASCO, ESMO,, NACB progesterone receptor (tissue) response Prognosis ASCO (do not use alone),, NACB (do not use alone), ACS HER, HER2, Predict response to ASCO, ESMO, ACS,, HER-2/neu Herceptin NACB (tissue) Prognosis, NACB Predict response to ASCO,, NACB anthracyclines CA 15-3, CA 27- Monitoring ASCO, ESMO, NACB, ACS 29 advanced disease CEA Monitoring ASCO, NACB advanced disease HER-2/neu Monitoring, NACB prognosis p53 Prognosis NACB Cervical HPV Risk assessment, NACB SCC Ag Monitoring NACB Ovarian CA 125 Monitoring ESMO, NACB, Differential NACB, diagnosis is suspicious pelvic mass Detection of ESMO, NACB, recurrence Prognosis ESMO, NACB βhcg Diagnosis, recurrence Gestational βhcg Monitoring ACS, NACB, trophoblastic Diagnosis ACS, NACB, ASCO = American Society of Clinical Oncology, ESMO = European Society of Medical Oncology, = National Comprehensive Cancer Network, NACB = National Academy of Clinical Biochemistry, ACS = American Cancer Society Male Genitourinary Tumor Type Marker Recommended Use Recommending Organizations* Prostate PSA Screening ACS, AUA, EAU, ESMO, NACB, Staging and prognosis AUA, EAU, ESMO,, NACB Monitoring AUA, EAU, ESMO,, NACB Follow-up and negative, NACB biopsy Germ cell βhcg and Diagnosis and differential ASCO, EAU, ESMO, NACB,

(testicular) AFP diagnosis of nonseminomatous germ cell cancer of the testes Staging and prognosis ASCO, EAU, ESMO, NACB, Monitoring ASCO, EAU, ESMO, NACB, Detecting recurrence ASCO, EAU, ESMO, NACB, ACS = American Cancer Society, ASCO = American Society of Clinical Oncology, AUA = American Urological Association, EAU = European Association of Urologists, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry, = National Comprehensive Cancer Network B-cell and T/NK-cell Lymphoma Tumor Type Marker Recommended Use Recommending Organizations CD3, CD4, CD5, CD10, (BCL-6), Diagnosis and, NACB CD20, CD45 (LCA), CD56CD79a, differentiation CD117 (c-kit), CD138 Cyclin D1, SP4 t(11;14) Diagnosis of MCL and multiple myeloma Ki-67 (MIB-1) Diagnosis HTLV Diagnosis and differentiation = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry Leukemia Tumor Type Marker Recommended Use Recommending Organizations AML c-kit (CD117) Prognosis ESMO = European Society of Medical Oncology, = National Comprehensive Cancer Network, NACB = National Academy of Clinical Biochemistry, WHO = World Health Organization Childhood Tumors Tumor Type Marker Recommended Use Neuroblastoma NSE Prognosis NACB HVA, VMA, Diagnosis, NACB catecholamines Skin Recommending Organizations Tumor Type Marker Recommended Use Recommending Organizations S-100, Diagnosis, usually used ACS, NACB Melanoma HMB45 in combination

(gp100) c-kit Response to therapy ACS ACS = American Cancer Society, NACB = National Academy of Clinical Biochemistry Thyroid/Parathyroid Tumor Type Marker Recommended Use Recommending Organizations Thyroglobulin Diagnosis,, AACE, NACB Well-differentiated Thyroglobulin (IHC) Diagnosis NACB Medullary thyroid Calcitonin Monitoring,, AACE, NACB carcinoma diagnosis CEA Diagnosis,, NACB = National Comprehensive Cancer Network, AACE = American Association of Clinical Endocrinologists, NACB = National Academy of Clinical Biochemistry